Related Experiment Video
Updated: Jul 5, 2025
08:13
Study of In Vivo Glucose Metabolism in High-fat Diet-fed Mice Using Oral Glucose Tolerance Test OGTT and Insulin Tolerance Test ITT
Published on: January 7, 2018
68.5K
Relationship Between Lipohypertrophy, Glycemic Control, and Insulin Dosing: A Systematic Meta-Analysis
Julia K Mader1, Ricardo Fornengo2, Ahmed Hassoun3
1Division of Endocrinology and Diabetology, Department of Internal Medicine, Medical University of Graz, Graz, Austria.
Diabetes Technology & Therapeutics
|January 12, 2024
Summary
Lipohypertrophy in diabetic patients on insulin therapy is linked to poorer glycemic control. This condition increases risks of hypoglycemia and requires higher insulin doses, impacting diabetes management.
Area of Science:
- Endocrinology
- Metabolic Diseases
- Pharmacology
Background:
- Lipohypertrophy is a common complication of insulin therapy in diabetes.
- Its impact on diabetes management remains unclear, lacking consensus.
- Understanding this link is crucial for optimizing patient care.
Purpose of the Study:
- To assess the correlation between lipohypertrophy and glycemic control in diabetic patients.
- To investigate the relationship between lipohypertrophy and insulin dosing.
- To synthesize existing evidence through systematic review and meta-analysis.
Main Methods:
- Systematic review and meta-analysis of studies published from 1990 to January 2023.
- Searched MEDLINE/PubMed, Embase, and CENTRAL databases, with additional hand-searching.
- Analyzed data on glycemic control and insulin dosing in patients with and without lipohypertrophy.
Main Results:
- Patients with lipohypertrophy showed higher HbA1c levels (MD: 0.55%) and increased daily insulin needs (MD: 7.68 IU).
- Increased likelihood of unexplained hypoglycemia (pOR: 6.98), overall hypoglycemia (pOR: 6.65), and glycemic variability (pOR: 5.24) was observed.
- 37 studies involving 5540 records were included in the meta-analysis.
Conclusions:
- Lipohypertrophy is associated with significantly worse glycemic control in diabetic patients.
- The condition correlates with increased hypoglycemia risk, glycemic variability, and higher insulin requirements.
- Addressing lipohypertrophy is essential for improving diabetes management outcomes.
Related Concept Videos
01:16Insulin: Dosing Regimen and Adverse Effects
175
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
175
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
204
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
204
01:15Diabetes: Management and Pharmacotherapy
285
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
285
01:06Oral Hypoglycemic Agents: Glinides
156
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
156
01:23Dipeptidyl Peptidase 4 Inhibitors
188
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
188
01:15Hypoglycemia and Glucagon
263
Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
263